These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 9793486)

  • 1. [Lipid lowering: myth or therapeutic necessity?].
    Dtsch Med Wochenschr; 1998 Oct; 123(40 Suppl):2-8. PubMed ID: 9793486
    [No Abstract]   [Full Text] [Related]  

  • 2. Treating lipid disorders.
    Manninen V; Mälkönen M; Tuomilehto J
    Am Heart J; 1979 May; 97(5):674-6. PubMed ID: 219673
    [No Abstract]   [Full Text] [Related]  

  • 3. [Indications for decreasing lipid values. Patients with healthy hearts with low HDL clearly profit].
    MMW Fortschr Med; 2000 Nov; 142(48):68. PubMed ID: 11138292
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacologic treatment of type 2 diabetic dyslipidemia.
    Moon YS; Kashyap ML
    Pharmacotherapy; 2004 Dec; 24(12):1692-713. PubMed ID: 15585439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Selective therapy of hyperlipidemias].
    Greten H
    MMW Munch Med Wochenschr; 1978 Dec; 120(50):1661-2. PubMed ID: 214703
    [No Abstract]   [Full Text] [Related]  

  • 6. [The anti-lipidemic effect of Minipress].
    Pados G; Iványi J; Földes I; Dudás M; Farsang C
    Orv Hetil; 1990 May; 131(21):1139-41. PubMed ID: 2362761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [AVERT study (Atorvastatin Versus Revascularization Treatment). Clinical advantage of aggressive lipid lowering].
    Z Kardiol; 1999 Mar; 88(3 Suppl):1-4. PubMed ID: 10330699
    [No Abstract]   [Full Text] [Related]  

  • 8. [Should lipid-lowering drugs be administered to normolipemic or mild hyperlipemic patients with coronary risk factors? Arguments for].
    de Teresa Galván E; Jiménez Navarro M
    Rev Esp Cardiol; 1996 Jul; 49(7):483-5. PubMed ID: 8754441
    [No Abstract]   [Full Text] [Related]  

  • 9. [Drug therapy of hyperlipidemias].
    Wolfram G
    Wien Med Wochenschr; 1981; 131(13-14):333-8. PubMed ID: 7281700
    [No Abstract]   [Full Text] [Related]  

  • 10. Management of dyslipidemia.
    Akel MM; Salti I
    J Med Liban; 2001; 49(5):274-8. PubMed ID: 12243421
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical inquiries. What is the best strategy for monitoring the lipid-lowering effects of medical therapy used for the primary prevention of coronary artery disease (CAD)?
    Sherrod JP; Krist A
    J Fam Pract; 2001 Nov; 50(11):928. PubMed ID: 11711006
    [No Abstract]   [Full Text] [Related]  

  • 12. [Should lipid-lowering drugs be administered to normolipemic or mild hyperlipemic patients with coronary risk factors? Arguments against].
    Brotons Cuixart C; Maiques Galán A
    Rev Esp Cardiol; 1996 Jul; 49(7):486-91. PubMed ID: 8754442
    [No Abstract]   [Full Text] [Related]  

  • 13. [High cholesterol levels are discriminated by new therapeutic recommendations].
    Olsson AG
    Lakartidningen; 2000 Apr; 97(16):1995-6. PubMed ID: 10826361
    [No Abstract]   [Full Text] [Related]  

  • 14. Management of patients with dyslipidaemia.
    Mann J; Chisholm A; Crooke M; Jackson R; Neutze J; North D; Swinburn B; White H; Wilcox J
    N Z Med J; 1995 Oct; 108(1010):444. PubMed ID: 7478355
    [No Abstract]   [Full Text] [Related]  

  • 15. Lipid-lowering drugs and low-fat diets.
    Palmer RH
    Curr Concepts Nutr; 1983; 12():101-9. PubMed ID: 6851627
    [No Abstract]   [Full Text] [Related]  

  • 16. Lipid abnormalities and coronary heart disease.
    Grundy SM
    Clin Symp; 1997; 49(4):1-32. PubMed ID: 9444788
    [No Abstract]   [Full Text] [Related]  

  • 17. Bezafibrate and lovastatin decrease the oxidizability of low-density lipoproteins in heart transplant recipients with hyperlidemia.
    Zambrana JL; López-Miranda J; Blanco A; Arizón JM; Jansen S; Paniagua JA; Jimenéz-Perepérez JA; Concha M; Pérez-Jiménez F
    J Heart Lung Transplant; 1998 Dec; 17(12):1213-9. PubMed ID: 9883763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [HMG-CoA reductase inhibitors in therapy of disorders of lipid metabolism].
    Windler E; Greten H
    Internist (Berl); 1993 Dec; 34(12):1107-14. PubMed ID: 8106206
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
    Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE
    J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal transplantation and dyslipidemia: characterization of a population and treatment with diet and low dose lovastatin.
    Downey P; Maiz A; Vaccarezza A; Pinto C; Retamal F; Martínez L
    Transplant Proc; 1995 Apr; 27(2):1803-5. PubMed ID: 7725511
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.